Table 4.
Clinical evaluation
| Post-procedure (n=90 patients) | 6-month follow-up (n=83 patients) | 18-month follow-up (n=73 patients) | |
| mRS score, n (%) | MD=1 | ||
| 0 | 78 (86.67) | 72 (86.75) | 60 (83.33) |
| 1 | 5 (5.56) | 5 (6.02) | 6 (8.33) |
| 2 | 4 (4.44) | 2 (2.41) | 1 (1.39) |
| 3 | 0 | 1 (1.0) | 0 |
| 4 | 1 (1.11) | 0 | 0 |
| 5 | 2 (2.22) | 0 | 0 |
| 6 | 0 | 3 (3.61) | 5* (6.94) |
| Neurologic deterioration, n (%)† | MD=1 | ||
| Absent | 83 (92.22) | 78 (97.5) | 63 (87.50) |
| Present | 7 (7.78) | 5 (6.02) | 9 (12.50) |
| Minor | NA | 3 (3.61) | 6 (8.33) |
| Moderate | NA | 0 | 0 |
| Severe | NA | 2 (2.41) | 3 (4.17) |
*The five patients evaluated mRS=6 at 18 months are the three patients with mRS=6 at 6 months plus two other patients who died between the 6-month and 18-month follow-ups and for whom the mRS score was attributed as 6 at 18 months.
†On post-procedure evaluations, neurologic deterioration was determined subjectively by the investigator compared with the clinical status on admission. At 6 and 18-month follow-ups, clinical deterioration was defined as an increase in mRS score compared with the corresponding post-procedure value.
MD, missing data, NA, not defined.